Hyperhidrosis Treatment Market Global Advancement and Latest Study Report 2020 to 2027

Business / By /

Hyperhidrosis is a rare disorder where excessive/abnormal sweating (occurring in feet, armpits, hands, face, and other body parts) happens in an individual, which is mostly unrelated to heat or exercise. Excessive perspiring can cause social anxiety and shame, which, in turn, affects the quality of life. The rising incidence of the excessive sweating disorder is linked to the disruption in lifestyle routines, sedentary work schedules, regular alcohol intakes, and unhealthy food habits.

Advertisements

The prevalence rate of hyperhidrosis is increasing globally. The prevalence rate of the disorder in the U.S. was around 5% in 2017, and more than half of the cases registered were of axillary hyperhidrosis. The number of treatment options for treating this condition is increasing and can be adopted as per the severity of the disease. Several regional governments are updating reimbursement implications for hyperhidrosis treatment. For instance, in 2019, the United States began a ICD-10-CM reimbursement scheme code for operating procedures and medications in hyperhidrosis cases. Growing awareness regarding the types of treatment alternatives available for managing severe perspiration to improve the quality of life is poised to boost hyperhidrosis treatment industry growth in the coming years.

Antiperspirants, botox injections, and anticholinergics are some of the commonly used treatments for excessive sweating. In 2016, a product for permanent treatment of excessive armpit sweating called miraDry was launched. Botox injection by Allergan is the only FDA approved injection for primary focal hyperhidrosis treatment. The growing interest of industry leaders in developing excessive perspiration related treatment and enhanced research & development funding is projected to supplement hyperhidrosis treatment share through 2027.

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/hyperhidrosis-treatment-market

Further key findings from the report suggest

  • The introduction of new treatment methods for hyperhidrosis like microwave therapy and a rise in hyperhidrosis research is providing impetus to industry growth. Industry players like Miramar Labs are offering an effective solution for sweating disorders like miraDry.
  • On the basis of disease type, the plantar hyperhidrosis disease segment is projected to grow at a CAGR of 5.1% over the analysis period.
  • Based on treatment type, the physiotherapy segment is estimated to generate revenue close to USD 240.1 million, exhibiting a growth rate of 6.3% through 2027. The growth is led by increasing patient awareness regarding novel physiotherapy techniques like iontophoresis.
  • On the basis of end-use, the hospitals & clinics segment held a major chunk of the hyperhidrosis market share in 2019 and is estimated to register a CAGR of 5.5% through 2027. The segmental growth can be attributed to factors like well-resourced diagnostic rooms, better health coverage for healthcare services, and the availability of highly skilled healthcare professionals.
  • In the regional landscape, North America remains the key revenue-generating region for the secondary generalized hyperhidrosis treatment market. In 2018, the region accounted for a whopping USD 388.7 million revenue share and is forecast to gain major traction over the analysis period. The regional growth can be attributed to the availability of state-of-art technologies, favorable reimbursement scenarios, a paradigm shift towards precision medicine, and rising awareness regarding excessive sweating treatment.
  • The Asia-Pacific region is anticipated to contribute significantly to the global generalized hyperhidrosis treatment market with a CAGR of 6.2% through 2027. The regional growth is a result of increased investment by the biotechnology and pharmaceutical companies in hyperhidrosis research.
  • Key players in the global hyperhidrosis treatment market are Allergan (Ireland), Dermira, Inc. (U.S), Brickell Biotech, Inc. (U.S), GlaxoSmithKline plc (UK), Ulthera, Inc. (U.S), TheraVida, Sientra Inc. (U.S), Revance Therapeutics , Inc. (U.S), and Dr. August Wolff GmbH (Germany), among others.

For the purpose of this report, Reports and Data has segmented the Global Hyperhidrosis Treatment market on the basis of disease type, treatment type, distribution channel, and region:

Disease type Outlook (Revenue in Million USD; 2016–2026)

  • Primary Focal Hyperhidrosis
  • Palmar Hyperhidrosis
  • Plantar Hyperhidrosis
  • Others

Treatment Type Outlook (Revenue in Million USD; 2016–2026)

  • Medications
    • Antiperspirants
      • Prescription strength antiperspirants
      • Over-the-counter antiperspirants
    • Anticholinergics
    • Botox (botulinum toxin) – A
  • Physiotherapy
  • Surgical Treatments
    • Invasive Treatments
    • Non-invasive Treatments
      • Laser Treatments
      • Microwave Energy Destruction of Sweat Glands

Distribution Channel (Revenue in Million USD; 2016–2026)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Prescription Stores

Regional Outlook (Revenue in USD Million; 2016–2026)

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa

 

Related Posts